The 17th European Headache Congress was held in Barcelona, Spain, and online, on 6-9 December 2023, with the theme of ‘Headache: Expanding the Horizon’.
Only 16 out of 29 European countries taking part in a recent survey provided reimbursement for CGRP mAbs. In general (hospital based) neurologists were permitted to prescribe CGRP mAbs, and sometimes this was extended to headache or pain specialists. Eligibility criteria for patients ranged from at least four monthly migraine days to criteria for chronic …
Read more »Real world data from the United Arab Emirates have underlined the safety and tolerability of combining CGRP mAbs with gepants in patients with migraine in clinical practice. In the retrospective study of 516 patients with episodic or chronic migraine taking CGRP mAbs, 234 were also taking a gepant (rimegepant: 215; ubrogepant 19). During follow up, …
Read more »Older patients with migraine and those with migraine-specific clinical features are most likely to be good responders to CGRP mAbs. These are the findings from the largest real world study of CGRP mAb treatment in patients with migraine, with data on a total of 5818 patients in seven European countries. Of the total population, 84.2% …
Read more »Patients with migraine and obesity do just as well with fremanezumab as those with a normal body mass index (BMI). Results of a post hoc analysis of data from the Phase 3 HALO-LTS and FOCUS trials in a total of 2437 patients with episodic or chronic migraine show a reduction in monthly migraine days (MMD) …
Read more »Preliminary data from the RAMO study suggest that CGRP mAbs are at least as effective as botulinumtoxinA at six and 12 months in patients with chronic migraine. In the study of 154 patients who had at least two previous treatment failures, monthly migraine days (MHD) at six months were reduced by approximately 12 days with …
Read more »Patients with migraine who are anxious, stressed or have emotional problems are least likely to respond to CGRP mAbs, according to results of a study evaluating super response versus non response to preventive treatments. In the study, 116 patients with chronic or episodic migraine who had failed at least three preventive therapies underwent treatment with …
Read more »Weight based dosing with eptinezumab was generally well tolerated by children and adolescents, according to results of an open label pharmacokinetic (PK) study which used a population PK (PopPK) model adapted to a paediatric population. The 20-week open label study (NCT04537429) evaluated a single intravenous infusion of eptinezumab in children and adolescents (aged 6-17 years) …
Read more »
Financial support was provided as GMG Knowledge Gap Grant from Pfizer Inc, Pfizer have provided only financial support and had no input into the content provided.
